株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

閉経後骨粗鬆症:世界の治験レビュー

Post Menopausal Osteoporosis Global Clinical Trials Review, H2, 2016

発行 GlobalData 商品コード 232270
出版日 ページ情報 英文 322 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
閉経後骨粗鬆症:世界の治験レビュー Post Menopausal Osteoporosis Global Clinical Trials Review, H2, 2016
出版日: 2016年09月30日 ページ情報: 英文 322 Pages
概要

当レポートでは、閉経後骨粗鬆症に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、主な先進国・新興国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤などの情報を盛り込んで、概略以下の構成でお届けします。

目次

イントロダクション

  • 閉経後骨粗鬆症
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の上位5ヶ国
    • 欧州の上位5ヶ国
    • 北米の主要国
    • 中東・アフリカの主要国
    • 中南米の主要国

G7諸国での治験件数:代謝系疾患の治験全体における閉経後骨粗鬆症の割合

G7諸国での治験件数:フェーズ(相)別

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:代謝系疾患の治験全体における閉経後骨粗鬆症の割合

E7諸国での治験件数:フェーズ(相)別

E7諸国での治験件数:進捗状況別

フェーズ(相)別の治験件数

  • 進行中の治験:フェーズ別

進捗状況別の治験件数

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

  • 閉経後骨粗鬆症治療薬の治験に参加している上位企業

有望な薬剤

治験のプロファイル

  • 代表的企業の治験の概要
    • F. Hoffmann-La Roche Ltd.
    • Eli Lilly and Company
    • Amgen Inc.
    • Merck & Co., Inc.
    • Sanofi
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Novartis AG
    • Radius Health, Inc.
    • Actavis plc
  • 代表的な研究機関・病院の治験の概要
    • Institut de Recherches Internationales Servier
    • University of California, San Francisco
    • University of Pittsburgh
    • National Institute of Arthritis and Musculoskeletal and Skin Diseases
    • Mayo Clinic
    • National Heart, Lung, and Blood Institute
    • Massachusetts General Hospital
    • National Center for Complementary and Alternative Medicine
    • Oregon Health and Science University
    • The National Institute of Diabetes and Digestive and Kidney Diseases

5つの代表的な治験のプロファイル

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC3794CTIDB

GlobalData's clinical trial report, "Post Menopausal Osteoporosis Global Clinical Trials Review, H2, 2016" provides an overview of Post Menopausal Osteoporosis clinical trials scenario. This report provides top line data relating to the clinical trials on Post Menopausal Osteoporosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • Clinical Trials by Region 6
  • Clinical Trials and Average Enrollment by Country 7
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
  • Top Five Countries Contributing to Clinical Trials in Europe 10
  • Top Countries Contributing to Clinical Trials in North America 11
  • Top Countries Contributing to Clinical Trials in Middle East and Africa 12
  • Top Five Countries Contributing to Clinical Trials in Central and South America 13
  • Clinical Trials by G7 Countries: Proportion of Post Menopausal Osteoporosis to Metabolic Disorders Clinical Trials 14
  • Clinical Trials by Phase in G7 Countries 15
  • Clinical Trials in G7 Countries by Trial Status 16
  • Clinical Trials by E7 Countries: Proportion of Post Menopausal Osteoporosis to Metabolic Disorders Clinical Trials 17
  • Clinical Trials by Phase in E7 Countries 18
  • Clinical Trials in E7 Countries by Trial Status 19
  • Clinical Trials by Phase 20
  • In Progress Trials by Phase 21
  • Clinical Trials by Trial Status 22
  • Clinical Trials by End Point Status 23
  • Subjects Recruited Over a Period of Time 24
  • Clinical Trials by Sponsor Type 25
  • Prominent Sponsors 26
  • Top Companies Participating in Post Menopausal Osteoporosis Therapeutics Clinical Trials 27
  • Prominent Drugs 29
  • Latest Clinical Trials News on Post Menopausal Osteoporosis 30
  • Sep 18, 2016: Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis 30
  • Sep 18, 2016: Radius Announces Publication of Additional Positive Results from the Phase 3 ACTIVE Trial of Abaloparatide-SC in JBMR 31
  • Sep 14, 2016: Amgen to present romosozumab at Investor Call 32
  • Sep 07, 2016: UCB to present results from Phase 3 FRAME Study at the American Society for Bone and Mineral Research Annual Meeting 32
  • Aug 16, 2016: JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women With Osteoporosis 33
  • Jul 20, 2016: Radius Health Announces Multiple Presentations at the American Society for Bone and Mineral Research 2016 Annual Meeting September 16-19, 2016 34
  • Clinical Trial Profile Snapshots 35

Appendix 319

  • Abbreviations 319
  • Definitions 319
  • Research Methodology 320
  • Secondary Research 320
  • About GlobalData 321
  • Contact Us 321
  • Disclaimer 321
  • Source 322

List of Tables

  • Post Menopausal Osteoporosis Therapeutics, Global, Clinical Trials by Region, 2016* 6
  • Post Menopausal Osteoporosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Post Menopausal Osteoporosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13
  • Proportion of Post Menopausal Osteoporosis to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 14
  • Post Menopausal Osteoporosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
  • Post Menopausal Osteoporosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
  • Proportion of Post Menopausal Osteoporosis to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 17
  • Post Menopausal Osteoporosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
  • Post Menopausal Osteoporosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
  • Post Menopausal Osteoporosis Therapeutics, Global, Clinical Trials by Phase, 2016* 20
  • Post Menopausal Osteoporosis Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
  • Post Menopausal Osteoporosis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
  • Post Menopausal Osteoporosis Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures

  • Post Menopausal Osteoporosis Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
  • Post Menopausal Osteoporosis Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
  • Post Menopausal Osteoporosis Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
  • Proportion of Post Menopausal Osteoporosis to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 14
  • Post Menopausal Osteoporosis Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
  • Post Menopausal Osteoporosis Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
  • Proportion of Post Menopausal Osteoporosis to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 17
  • Post Menopausal Osteoporosis Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
  • Post Menopausal Osteoporosis Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
  • Post Menopausal Osteoporosis Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
  • Post Menopausal Osteoporosis Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
  • Post Menopausal Osteoporosis Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
  • Post Menopausal Osteoporosis Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
  • Post Menopausal Osteoporosis Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
  • GlobalData Methodology 320
Back to Top